DIADEMA PARTNERS LP
13F Reported Value
ⓘ$791.3M
incl. option notional
Equity Holdings
ⓘ$283.2M
Option Notional
ⓘ$508.2M
$179.1M puts / $329.0M calls
Holdings
149
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
DIADEMA PARTNERS LP disclosed 149 positions worth $791.3M in its Form 13F-HR for Q2 2026 — $283.2M in common stock plus $508.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $VKTX (Viking Therapeutics, Inc.) calls, followed by $ABVX and $BMY. During the quarter the fund opened 67 new positions and exited 62 — including a new stake in $BMY and a full exit from $VRTX. The portfolio is most concentrated in Healthcare (92.9% of disclosed assets). All figures are sourced directly from DIADEMA PARTNERS LP’s Form 13F-HR filing with the SEC under CIK 2026172.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $47.6M1,220,800 sh
- —
Quality
$46.5M349,200 sh - 70.4#219
Quality
$34.6M600,000 sh - —
Quality
$33.6M252,400 sh - 71.3
Quality
$28.7M52,989 sh - —
Quality
$26.1M139,218 sh - —
Quality
$21.6M163,644 sh - —
Quality
$19.1M493,664 sh - 70.4
Quality
$19.0M330,600 sh BRIDGEBIO PHARMA INC - NOTE 1.750% 3/0
—Quality
$18.6M250,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Viking Therapeutics, Inc.$VKTXCALL | — | $47.6M | 1,220,800 |
 Abivax S.A.$ABVXCALL | — | $46.5M | 349,200 |
 BRISTOL MYERS SQUIBB CO$BMYCALL | 70.4#219 | $34.6M | 600,000 |
| Abivax S.A.$ABVXPUT | — | $33.6M | 252,400 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $28.7M | 52,989 |
 Revolution Medicines, Inc.$RVMD | — | $26.1M | 139,218 |
| Abivax S.A.$ABVX | — | $21.6M | 163,644 |
 Cogent Biosciences, Inc.$COGT | — | $19.1M | 493,664 |
| BRISTOL MYERS SQUIBB CO$BMYPUT | 70.4 | $19.0M | 330,600 |
| BRIDGEBIO PHARMA INC - NOTE 1.750% 3/0 | — | $18.6M | 250,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of DIADEMA PARTNERS LP's 149 positions.
Showing top 10 of 149 holdings.
Sector Allocation
Healthcare
$263.0M
Other
$20.1M
Financials
$102,479
Full Holdings — DIADEMA PARTNERS LP (Q2 2026)
All 149 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $VKTXCALL | Viking Therapeutics, Inc. | $47.6M | — | +85% | — |
| 2 | $ABVXCALL | Abivax S.A. | $46.5M | — | +249% | — |
| 3 | $BMYCALL | BRISTOL MYERS SQUIBB CO | $34.6M | — | NEW | 70.4 |
| 4 | $ABVXPUT | Abivax S.A. | $33.6M | — | +152% | — |
| 5 | $UTHR | UNITED THERAPEUTICS Corp | $28.7M | 10.1% | +94% | 71.3 |
| 6 | $RVMD | Revolution Medicines, Inc. | $26.1M | 9.2% | +72% | — |
| 7 | $ABVX | Abivax S.A. | $21.6M | 7.6% | +115% | — |
| 8 | $COGT | Cogent Biosciences, Inc. | $19.1M | 6.8% | +53% | — |
| 9 | $BMYPUT | BRISTOL MYERS SQUIBB CO | $19.0M | — | NEW | 70.4 |
| 10 | — | BRIDGEBIO PHARMA INC - NOTE 1.750% 3/0 | $18.6M | 6.6% | +0% | — |
| 11 |  $CORTCALL | CORCEPT THERAPEUTICS INC | $17.9M | — | +30% | 57.8 |
| 12 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $17.9M | 6.3% | +111% | 58.2 |
| 13 | $VKTX | Viking Therapeutics, Inc. | $17.2M | 6.1% | -16% | — |
| 14 |  $KYMRCALL | Kymera Therapeutics, Inc. | $17.2M | — | NEW | 28.4 |
| 15 |  $NVSPUT | NOVARTIS AG | $15.7M | — | NEW | — |
| 16 |  $QUREPUT | uniQure N.V. | $13.8M | — | +0% | — |
| 17 | $VKTXPUT | Viking Therapeutics, Inc. | $13.7M | — | NEW | — |
| 18 |  $BIIBCALL | BIOGEN INC. | $13.0M | — | NEW | 64.7 |
| 19 |  $CAPRPUT | CAPRICOR THERAPEUTICS, INC. | $12.9M | — | -14% | 13.6 |
| 20 |  $SMMTCALL | Summit Therapeutics Inc. | $12.5M | — | NEW | — |
| 21 |  $LLYPUT | ELI LILLY & Co | $12.0M | — | NEW | 87.5 |
| 22 |  $INCYPUT | INCYTE CORP | $11.9M | — | +0% | 77.4 |
| 23 |  $EWTX | Edgewise Therapeutics, Inc. | $11.1M | 3.9% | NEW | — |
| 24 | $QURECALL | uniQure N.V. | $10.8M | — | -6% | — |
| 25 |  $BNTXCALL | BioNTech SE | $9.3M | — | NEW | — |
| 26 |  $KOD | Kodiak Sciences Inc. | $8.5M | 3.0% | +13% | — |
| 27 |  $IMCR | Immunocore Holdings plc | $8.1M | 2.9% | +32% | — |
| 28 | $CAPRCALL | CAPRICOR THERAPEUTICS, INC. | $7.9M | — | +0% | 13.6 |
| 29 | $NVSCALL | NOVARTIS AG | $7.8M | — | NEW | — |
| 30 |  $REPLCALL | Replimune Group, Inc. | $7.7M | — | +239% | — |
| 31 | $KODCALL | Kodiak Sciences Inc. | $7.7M | — | NEW | — |
| 32 |  $FDMT | 4D Molecular Therapeutics, Inc. | $7.6M | 2.7% | NEW | 34.5 |
| 33 |  $MRNAPUT | Moderna, Inc. | $7.0M | — | -37% | 21.2 |
| 34 |  $HIMSCALL | Hims & Hers Health, Inc. | $6.9M | — | NEW | 53.4 |
| 35 |  $RCUS | Arcus Biosciences, Inc. | $6.9M | 2.4% | -6% | 8.5 |
| 36 | $HIMSPUT | Hims & Hers Health, Inc. | $6.7M | — | NEW | 53.4 |
| 37 |  $CRBPCALL | Corbus Pharmaceuticals Holdings, Inc. | $5.9M | — | +450% | — |
| 38 |  $SLSCALL | SELLAS Life Sciences Group, Inc. | $5.9M | — | +33% | — |
| 39 | $KODPUT | Kodiak Sciences Inc. | $5.7M | — | -41% | — |
| 40 |  $ALMSCALL | ALUMIS INC. | $5.6M | — | +100% | 7.1 |
| 41 |  $RPRXCALL | Royalty Pharma plc | $5.6M | — | NEW | — |
| 42 |  $JNJ | JOHNSON & JOHNSON | $5.6M | 2.0% | -59% | 69 |
| 43 | $REPLPUT | Replimune Group, Inc. | $5.6M | — | +9% | — |
| 44 |  $BIOACALL | BioAge Labs, Inc. | $4.9M | — | NEW | 26.8 |
| 45 |  $NVO | NOVO NORDISK A S | $4.8M | 1.7% | +586% | — |
| 46 |  $BHVNCALL | Biohaven Ltd. | $4.7M | — | +0% | — |
| 47 |  $TENXCALL | TENAX THERAPEUTICS, INC. | $4.5M | — | NEW | — |
| 48 |  $CRVS | Corvus Pharmaceuticals, Inc. | $4.4M | 1.6% | +20% | — |
| 49 |  $RLAY | Relay Therapeutics, Inc. | $4.3M | 1.5% | NEW | 19.5 |
| 50 |  $TGTXCALL | TG THERAPEUTICS, INC. | $4.2M | — | NEW | 69.3 |
| 51 |  $GLUECALL | Monte Rosa Therapeutics, Inc. | $4.1M | — | NEW | 30.3 |
| 52 | $RCUSCALL | Arcus Biosciences, Inc. | $3.8M | — | NEW | 8.5 |
| 53 |  $UNCYCALL | Unicycive Therapeutics, Inc. | $3.7M | — | NEW | — |
| 54 |  $ZYME | Zymeworks Inc. | $3.7M | 1.3% | +0% | 8.7 |
| 55 |  $AMGNCALL | AMGEN INC | $3.6M | — | NEW | 79.2 |
| 56 | $BIOA | BioAge Labs, Inc. | $3.6M | 1.3% | +144% | 26.8 |
| 57 |  $TSHA | Taysha Gene Therapies, Inc. | $3.6M | 1.3% | NEW | 4.9 |
| 58 |  $NTLACALL | Intellia Therapeutics, Inc. | $3.4M | — | +0% | 19.9 |
| 59 |  $CLDXPUT | Celldex Therapeutics, Inc. | $3.2M | — | NEW | 8.4 |
| 60 |  $PCVXCALL | Vaxcyte, Inc. | $3.1M | — | +0% | — |
| 61 |  $NRIX | Nurix Therapeutics, Inc. | $2.9M | 1.0% | NEW | 6.4 |
| 62 | $SMMTPUT | Summit Therapeutics Inc. | $2.9M | — | NEW | — |
| 63 | $PCVXPUT | Vaxcyte, Inc. | $2.8M | — | NEW | — |
| 64 | $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $2.8M | 1.0% | -32% | — |
| 65 |  $INDV | Indivior Pharmaceuticals, Inc. | $2.8M | 1.0% | -5% | 58.5 |
| 66 |  $IVA | Inventiva S.A. | $2.7M | 1.0% | +110% | — |
| 67 | $NVOPUT | NOVO NORDISK A S | $2.7M | — | +0% | — |
| 68 |  $ORKA | Oruka Therapeutics, Inc. | $2.6M | 0.9% | NEW | — |
| 69 | $PCVX | Vaxcyte, Inc. | $2.6M | 0.9% | +80% | — |
| 70 |  $CYTKPUT | CYTOKINETICS INC | $2.6M | — | -85% | 28.1 |
| 71 |  $RLMD | RELMADA THERAPEUTICS, INC. | $2.5M | 0.9% | +80% | — |
| 72 |  $VERA | Vera Therapeutics, Inc. | $2.5M | 0.9% | NEW | — |
| 73 | $VERAPUT | Vera Therapeutics, Inc. | $2.1M | — | NEW | — |
| 74 |  $CELCCALL | Celcuity Inc. | $2.1M | — | +13% | — |
| 75 |  $ANNXCALL | Annexon, Inc. | $2.0M | — | +0% | — |
| 76 |  $SEPNPUT | Septerna, Inc. | $2.0M | — | NEW | 59.2 |
| 77 | $CRVSCALL | Corvus Pharmaceuticals, Inc. | $2.0M | — | +25% | — |
| 78 |  $CTNM | Contineum Therapeutics, Inc. | $2.0M | 0.7% | NEW | — |
| 79 |  $BCYC | BICYCLE THERAPEUTICS PLC | $2.0M | 0.7% | -3% | — |
| 80 | $GLUE | Monte Rosa Therapeutics, Inc. | $1.9M | 0.7% | -58% | 30.3 |
| 81 | $CLDXCALL | Celldex Therapeutics, Inc. | $1.9M | — | NEW | 8.4 |
| 82 |  $VRDN | Viridian Therapeutics, Inc.\DE | $1.8M | 0.7% | NEW | 27.2 |
| 83 |  $MGNX | MACROGENICS INC | $1.7M | 0.6% | -38% | 39.6 |
| 84 |  $PRQR | ProQR Therapeutics N.V. | $1.7M | 0.6% | +414% | — |
| 85 |  $ADMACALL | ADMA BIOLOGICS, INC. | $1.7M | — | NEW | 69.7 |
| 86 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $1.6M | 0.6% | +200% | — |
| 87 |  $ARDX | ARDELYX, INC. | $1.5M | 0.6% | NEW | 41.9 |
| 88 |  $CUE | Cue Biopharma, Inc. | $1.5M | 0.5% | -63% | 28.9 |
| 89 |  $MLYS | Mineralys Therapeutics, Inc. | $1.5M | 0.5% | +114% | — |
| 90 |  $EYPTCALL | EyePoint, Inc. | $1.5M | — | +0% | 3.5 |
| 91 | $SLSPUT | SELLAS Life Sciences Group, Inc. | $1.5M | — | NEW | — |
| 92 | — | PROTHENA CORP PLC - SHS | $1.5M | 0.5% | NEW | — |
| 93 |  $VYGR | Voyager Therapeutics, Inc. | $1.4M | 0.5% | -2% | 8.1 |
| 94 | $UNCY | Unicycive Therapeutics, Inc. | $1.4M | 0.5% | +186% | — |
| 95 |  $PHAT | Phathom Pharmaceuticals, Inc. | $1.4M | 0.5% | +138% | 40.9 |
| 96 |  $EOLSCALL | Evolus, Inc. | $1.4M | — | +60% | 39 |
| 97 |  $SYRE | Spyre Therapeutics, Inc. | $1.3M | 0.5% | NEW | — |
| 98 |  $HELP | CYBIN INC. | $1.3M | 0.5% | NEW | — |
| 99 |  $CRMDPUT | CorMedix Inc. | $1.3M | — | +0% | 78.6 |
| 100 |  $EDITCALL | Editas Medicine, Inc. | $1.3M | — | NEW | 33.4 |
| 101 |  $EQ | Equillium, Inc. | $1.3M | 0.5% | -8% | 11.7 |
| 102 |  $PYXSCALL | Pyxis Oncology, Inc. | $1.2M | — | NEW | 16 |
| 103 |  $XERS | Xeris Biopharma Holdings, Inc. | $1.1M | 0.4% | +0% | 56.5 |
| 104 |  $PHVS | Pharvaris N.V. | $1.0M | 0.4% | +0% | — |
| 105 |  $HRMY | Harmony Biosciences Holdings, Inc. | $978,118 | 0.3% | -71% | 71.4 |
| 106 |  $RNAC | Cartesian Therapeutics, Inc. | $907,134 | 0.3% | NEW | 8 |
| 107 |  $AQSTCALL | Aquestive Therapeutics, Inc. | $892,736 | — | NEW | 14.5 |
| 108 |  $RIGL | RIGEL PHARMACEUTICALS INC | $892,562 | 0.3% | NEW | 73.9 |
| 109 | $SMMT | Summit Therapeutics Inc. | $874,200 | 0.3% | NEW | — |
| 110 |  $PGEN | PRECIGEN, INC. | $771,170 | 0.3% | +145% | 29.6 |
| 111 |  $DFTX | Definium Therapeutics, Inc. | $726,815 | 0.3% | NEW | — |
| 112 |  $PTHS | Pelthos Therapeutics Inc. | $700,085 | 0.3% | +0% | 17.5 |
| 113 |  $PEPG | PepGen Inc. | $671,911 | 0.2% | +147% | — |
| 114 | $HELPCALL | CYBIN INC. | $661,000 | — | NEW | — |
| 115 | $VYGRCALL | Voyager Therapeutics, Inc. | $525,000 | — | +0% | 8.1 |
| 116 |  $CGONCALL | CG Oncology, Inc. | $518,665 | — | NEW | 27 |
| 117 |  $ELVN | Enliven Therapeutics, Inc. | $507,500 | 0.2% | +3982% | — |
| 118 |  $CNTB | Connect Biopharma Holdings Ltd | $468,824 | 0.2% | -2% | — |
| 119 |  $LRMR | Larimar Therapeutics, Inc. | $447,243 | 0.2% | -12% | — |
| 120 |  $ELTXCALL | Elicio Therapeutics, Inc. | $438,311 | — | NEW | — |
| 121 | $ELTXPUT | Elicio Therapeutics, Inc. | $391,000 | — | NEW | — |
| 122 |  $CLRB | Cellectar Biosciences, Inc. | $384,588 | 0.1% | NEW | — |
| 123 |  $FHTX | Foghorn Therapeutics Inc. | $326,511 | 0.1% | -16% | 16.1 |
| 124 |  $AYTU | AYTU BIOPHARMA, INC | $319,374 | 0.1% | -58% | 23.4 |
| 125 |  $OCGN | Ocugen, Inc. | $306,000 | 0.1% | +0% | — |
| 126 |  $INOCALL | INOVIO PHARMACEUTICALS, INC. | $302,720 | — | +266% | 8.3 |
| 127 |  $URGN | UroGen Pharma Ltd. | $262,642 | 0.1% | -69% | — |
| 128 | $AMGN | AMGEN INC | $214,645 | 0.1% | NEW | 79.2 |
| 129 |  $HRTX | HERON THERAPEUTICS, INC. /DE/ | $195,783 | 0.1% | NEW | 24.7 |
| 130 |  $TLPH | TALPHERA, INC. | $158,170 | 0.1% | +0% | — |
| 131 | $ANNX | Annexon, Inc. | $157,116 | 0.1% | -79% | — |
| 132 |  $MNPR | Monopar Therapeutics | $150,922 | 0.1% | +0% | — |
| 133 |  $LAKE | LAKELAND INDUSTRIES INC | $150,815 | 0.1% | NEW | 35.5 |
| 134 |  $UPB | Upstream Bio, Inc. | $132,124 | 0.1% | -12% | 19.7 |
| 135 |  $MGTX | MeiraGTx Holdings plc | $113,052 | 0.0% | NEW | — |
| 136 |  $JATT | JATT II Acquisition Corp. | $102,479 | 0.0% | NEW | — |
| 137 |  $KLRA | Kailera Therapeutics, Inc. | $79,771 | 0.0% | NEW | — |
| 138 |  $MNKD | MANNKIND CORP | $68,173 | 0.0% | -91% | 37.2 |
| 139 |  $ENTX | Entera Bio Ltd. | $41,170 | 0.0% | +0% | — |
| 140 |  $SPRY | ARS Pharmaceuticals, Inc. | $38,929 | 0.0% | NEW | 20.3 |
| 141 |  $APRE | Aprea Therapeutics, Inc. | $36,029 | 0.0% | NEW | — |
| 142 |  $TVRD | Tvardi Therapeutics, Inc. | $31,553 | 0.0% | NEW | — |
| 143 |  $VTGNCALL | Vistagen Therapeutics, Inc. | $13,040 | — | NEW | — |
| 144 |  $NXTC | NextCure, Inc. | $12,387 | 0.0% | NEW | — |
| 145 |  $ATYRPUT | aTYR PHARMA INC | $7,460 | — | +0% | — |
| 146 | $MGTXCALL | MeiraGTx Holdings plc | $6,755 | — | NEW | — |
| 147 |  $JBIOPUT | Jade Biosciences, Inc. | $3,174 | — | +0% | — |
| 148 |  $ERASCALL | Erasca, Inc. | $1,832 | — | NEW | — |
| 149 | $CUECALL | Cue Biopharma, Inc. | $6 | — | NEW | 28.9 |
New Positions (67)
$BMYCALL BRISTOL MYERS SQUIBB CO$34.6M$BMYPUT BRISTOL MYERS SQUIBB CO$19.0M$KYMRCALL Kymera Therapeutics, Inc.$17.2M$NVSPUT NOVARTIS AG$15.7M$VKTXPUT Viking Therapeutics, Inc.$13.7M$BIIBCALL BIOGEN INC.$13.0M$SMMTCALL Summit Therapeutics Inc.$12.5M$LLYPUT ELI LILLY & Co$12.0M$EWTX Edgewise Therapeutics, Inc.$11.1M$BNTXCALL BioNTech SE$9.3M$NVSCALL NOVARTIS AG$7.8M$FDMT 4D Molecular Therapeutics, Inc.$7.6M$HIMSCALL Hims & Hers Health, Inc.$6.9M$HIMSPUT Hims & Hers Health, Inc.$6.7M$RPRXCALL Royalty Pharma plc$5.6MExited Positions (62)
$VRTXCALL VERTEX PHARMACEUTICALS INC / MA
$LQDACALL Liquidia Corp$UTHRCALL UNITED THERAPEUTICS Corp
$APGECALL Apogee Therapeutics, Inc.$RVMDPUT Revolution Medicines, Inc.
$MRKPUT Merck & Co., Inc.$UTHRPUT UNITED THERAPEUTICS Corp
$JAZZ Jazz Pharmaceuticals plc
$TERN Terns Pharmaceuticals, Inc.
$ROIVPUT Roivant Sciences Ltd.$INCY INCYTE CORP$TGTX TG THERAPEUTICS, INC.$EWTXCALL Edgewise Therapeutics, Inc.
$BBIO BridgeBio Pharma, Inc.
$GPCRPUT Structure Therapeutics Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for DIADEMA PARTNERS LP including:
Track DIADEMA PARTNERS LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for DIADEMA PARTNERS LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: DIADEMA PARTNERS LP
13F Pro is an AI hedge fund tracker and stock research platform. For DIADEMA PARTNERS LP (SEC CIK: 2026172), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DIADEMA PARTNERS LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.